Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT phase 2b/3 trial of inhaled AV-101 in pulmonary arterial hypertension
MOH_2022-11-10_012172Phase 3Completed
- Sponsor
- Aerovate Therapeutics
- Start
- Apr 2022
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 4-chlorokynurenine and imatinib in pulmonary arterial hypertension (PAH) (6 arms), sponsored by Aerovate Therapeutics. Primary endpoints: Placebo-corrected change in pulmonary vascular resistance and Placebo-corrected change in 6-minute walk distance. Started Apr 2022; status: completed.
02
Drugs
4-chlorokynurenineimatinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2022-11-10_012172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-10_012172.